Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166

Benzinga · 07/08 16:56
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $168 to $166.